TIUM.U Stock Overview
Through its subsidiaries, produces and sells medical cannabis in Florida, Pennsylvania, and Texas. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Cansortium Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.09 |
| 52 Week High | US$0.28 |
| 52 Week Low | US$0.075 |
| Beta | 3.07 |
| 11 Month Change | -37.93% |
| 3 Month Change | -37.93% |
| 1 Year Change | -18.18% |
| 33 Year Change | -88.00% |
| 5 Year Change | -83.64% |
| Change since IPO | -95.38% |
Recent News & Updates
Cansortium Inc. (CSE:TIUM.U) Stock's 38% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Nov 07
Cansortium (CSE:TIUM.U) Seems To Be Using A Lot Of Debt
Oct 25Cansortium Inc. (CSE:TIUM.U) Soars 30% But It's A Story Of Risk Vs Reward
Sep 04Cansortium Inc.'s (CSE:TIUM.U) CEO Compensation Is Looking A Bit Stretched At The Moment
Aug 21Recent updates
Cansortium Inc. (CSE:TIUM.U) Stock's 38% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Nov 07Cansortium (CSE:TIUM.U) Seems To Be Using A Lot Of Debt
Oct 25Cansortium Inc. (CSE:TIUM.U) Soars 30% But It's A Story Of Risk Vs Reward
Sep 04Cansortium Inc.'s (CSE:TIUM.U) CEO Compensation Is Looking A Bit Stretched At The Moment
Aug 21Slammed 32% Cansortium Inc. (CSE:TIUM.U) Screens Well Here But There Might Be A Catch
Jul 11Cansortium Inc.'s (CSE:TIUM.U) Shares Not Telling The Full Story
Jan 15Is Cansortium (CSE:TIUM.U) Using Too Much Debt?
Nov 30Is Cansortium (CSE:TIUM.U) Using Debt Sensibly?
Sep 01Cansortium Inc. (CSE:TIUM.U) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough
Jul 28An Intrinsic Calculation For Cansortium Inc. (CSE:TIUM.U) Suggests It's 26% Undervalued
Mar 08Does Cansortium (CSE:TIUM.U) Have A Healthy Balance Sheet?
Jan 09Here's Why Cansortium (CSE:TIUM.U) Has A Meaningful Debt Burden
Sep 09Shareholder Returns
| TIUM.U | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 12.5% | -2.4% | 0.4% |
| 1Y | -18.2% | -22.8% | 21.4% |
Return vs Industry: TIUM.U exceeded the Canadian Pharmaceuticals industry which returned -22.8% over the past year.
Return vs Market: TIUM.U underperformed the Canadian Market which returned 21.4% over the past year.
Price Volatility
| TIUM.U volatility | |
|---|---|
| TIUM.U Average Weekly Movement | 18.5% |
| Pharmaceuticals Industry Average Movement | 11.6% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.7% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: TIUM.U's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: TIUM.U's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Robert Beasley | getfluent.com |
Cansortium Inc., through its subsidiaries, produces and sells medical cannabis in Florida, Pennsylvania, and Texas. The company’s medical cannabis products are offered in oral drops, capsules, topicals, syringes, dried flower, pre-rolls, cartridges, concentrates, and edibles under the Fluent brand name. It also sells various third-party branded medical cannabis products.
Cansortium Inc. Fundamentals Summary
| TIUM.U fundamental statistics | |
|---|---|
| Market cap | US$28.70m |
| Earnings (TTM) | -US$13.23m |
| Revenue (TTM) | US$103.30m |
0.3x
P/S Ratio-2.1x
P/E RatioIs TIUM.U overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TIUM.U income statement (TTM) | |
|---|---|
| Revenue | US$103.30m |
| Cost of Revenue | US$40.24m |
| Gross Profit | US$63.06m |
| Other Expenses | US$76.29m |
| Earnings | -US$13.23m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.044 |
| Gross Margin | 61.04% |
| Net Profit Margin | -12.81% |
| Debt/Equity Ratio | 1,174.6% |
How did TIUM.U perform over the long term?
See historical performance and comparison